These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 15270197)

  • 1. Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals.
    Chen F; David D; Ferrari A; Götz J
    Curr Drug Targets; 2004 Aug; 5(6):503-15. PubMed ID: 15270197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
    Stancu IC; Ferraiolo M; Terwel D; Dewachter I
    Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology.
    Song L; Lu SX; Ouyang X; Melchor J; Lee J; Terracina G; Wang X; Hyde L; Hess JF; Parker EM; Zhang L
    Mol Neurodegener; 2015 Mar; 10():14. PubMed ID: 25881209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau Abnormalities and the Potential Therapy in Alzheimer's Disease.
    Almansoub HAMM; Tang H; Wu Y; Wang DQ; Mahaman YAR; Wei N; Almansob YAM; He W; Liu D
    J Alzheimers Dis; 2019; 67(1):13-33. PubMed ID: 30507581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau and transgenic animal models.
    Götz J
    Brain Res Brain Res Rev; 2001 Jul; 35(3):266-86. PubMed ID: 11423157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
    Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
    Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
    Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
    J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of tau phosphorylation and cleavage in neuronal cell death.
    Chun W; Johnson GV
    Front Biosci; 2007 Jan; 12():733-56. PubMed ID: 17127334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic Drosophila models of Alzheimer's disease and tauopathies.
    Iijima-Ando K; Iijima K
    Brain Struct Funct; 2010 Mar; 214(2-3):245-62. PubMed ID: 19967412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies.
    Sorrentino G; Bonavita V
    Neurol Sci; 2007 Apr; 28(2):63-71. PubMed ID: 17464468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-translational modifications of tau protein in Alzheimer's disease.
    Gong CX; Liu F; Grundke-Iqbal I; Iqbal K
    J Neural Transm (Vienna); 2005 Jun; 112(6):813-38. PubMed ID: 15517432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P301 L, an FTDP-17 Mutant, Exhibits Enhanced Glycation in vitro.
    Sonawane SK; Chinnathambi S
    J Alzheimers Dis; 2020; 75(1):61-71. PubMed ID: 32250308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.
    Liu K; Liu Y; Li L; Qin P; Iqbal J; Deng Y; Qing H
    Biochim Biophys Acta; 2016 Feb; 1862(2):192-201. PubMed ID: 26655600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation.
    Pérez M; Ribe E; Rubio A; Lim F; Morán MA; Ramos PG; Ferrer I; Isla MT; Avila J
    Neuroscience; 2005; 130(2):339-47. PubMed ID: 15664690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.
    Brandt R; Hundelt M; Shahani N
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):331-54. PubMed ID: 15615650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of tau pathology in tau transgenic models.
    Brion JP; Ando K; Heraud C; Leroy K
    Biochem Soc Trans; 2010 Aug; 38(4):996-1000. PubMed ID: 20658992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-translational modifications of tau protein: implications for Alzheimer's disease.
    Martin L; Latypova X; Terro F
    Neurochem Int; 2011 Mar; 58(4):458-71. PubMed ID: 21215781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer's disease.
    García-Escudero V; Ruiz-Gabarre D; Gargini R; Pérez M; García E; Cuadros R; Hernández IH; Cabrera JR; García-Escudero R; Lucas JJ; Hernández F; Ávila J
    Acta Neuropathol; 2021 Jul; 142(1):159-177. PubMed ID: 33934221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations
    Bardai FH; Wang L; Mutreja Y; Yenjerla M; Gamblin TC; Feany MB
    J Neurosci; 2018 Jan; 38(1):108-119. PubMed ID: 29138281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.
    Ando K; Dourlen P; Sambo AV; Bretteville A; Bélarbi K; Vingtdeux V; Eddarkaoui S; Drobecq H; Ghestem A; Bégard S; Demey-Thomas E; Melnyk P; Smet C; Lippens G; Maurage CA; Caillet-Boudin ML; Verdier Y; Vinh J; Landrieu I; Galas MC; Blum D; Hamdane M; Sergeant N; Buée L
    Neurobiol Aging; 2013 Mar; 34(3):757-69. PubMed ID: 22926167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.